Statute Details
- Title: Medicines (Prohibition of Sale, Supply and Importation) Order
- Act Code: MA1975-OR4
- Legislative Type: Subsidiary legislation (Order)
- Authorising Act: Medicines Act (Chapter 176, Section 30)
- Current Status: Current version as at 27 Mar 2026
- Key Provisions: Section 2 (definitions); Section 3 (restriction on sale/supply/import of medicinal products); Section 4 (restrictions for Chinese proprietary medicines); Section 5 (prohibition for Chinese proprietary medicines containing poisons)
- Schedules: First Schedule (poisons allowed in Chinese proprietary medicines); Second Schedule (poisons limits/conditions)
- Notable Amendments (selected): S 657/2019 (effective 01/01/2020); S 711/2012 (effective 01/01/2013); S 563/2022 (effective 01/08/2022)
What Is This Legislation About?
The Medicines (Prohibition of Sale, Supply and Importation) Order (“the Order”) is a regulatory instrument that restricts when and how medicinal products may be sold, supplied, or imported in Singapore. In plain terms, it creates legal “do not sell / do not supply / do not import” rules for medicines that are unsafe, out of specification, or otherwise prohibited by reference to expiry dates, quality/purity standards, and specified chemical or microbiological limits.
The Order is particularly important for two categories of products. First, it applies broadly to “medicinal products” (including conventional medicines) by prohibiting sale/supply/import of products that are expired, harmful/unsafe, or exceed specified quantities of certain substances. Second, it contains a more targeted regime for “Chinese proprietary medicines” (CPMs), including strict microbiological thresholds for oral and external CPMs and a special prohibition for CPMs containing “poisons” unless narrow conditions are met.
For practitioners, the Order functions as a compliance and enforcement baseline. It does not replace the Medicines Act or the broader licensing framework; rather, it operates alongside them by setting mandatory restrictions that apply to persons engaged in sale, supply, and importation. Violations can expose businesses and individuals to regulatory action and potential criminal or administrative consequences under the Medicines Act regime.
What Are the Key Provisions?
1) Definitions (Section 2)
Section 2 defines key terms used in the Order. Most notably, “Chinese proprietary medicine” is defined by reference to the Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order. This cross-reference matters: whether a product is a “Chinese proprietary medicine” is not determined solely by marketing labels, but by the legal definition in the referenced exemption order. The definition of “expiry date” is also provided, capturing both the “date after which” and the “month and year after” end-of-use concepts, as well as “date before which” and “month and year before” beginning-of-use concepts.
2) General restriction on sale, supply and importation of medicinal products (Section 3)
Section 3 is the Order’s core general rule. Subject to an exception in sub-paragraph (1A), “a person must not sell or supply to any other person any medicinal product” if any of the following apply:
- Expired products: the product is after the expiry date stated on the label on the container or package immediately enclosing the container.
- Harmful/unsafe or out of specification: the product is harmful or unsafe, or not in conformity as regards strength, quality or purity with the specification registered with the licensing authority (or, if not registered, with the manufacturer’s specification).
- Excess substances: the product contains any substances in excess of the respective quantities specified in the First Schedule.
Important exception—mercury in topical antiseptics (Section 3(1A))
Section 3(1A) introduces a specific prohibition: a person must not sell, supply or import any topical antiseptic that contains mercury or any compound of mercury. This is a strict, product-ingredient-based rule. Even if a topical antiseptic is otherwise within specification and not expired, the presence of mercury (or mercury compounds) triggers the prohibition.
Product licence carve-out (Section 3(2))
Section 3(2) provides that the “excess substances” prohibition in Section 3(1)(c) does not apply to any medicinal product for which a product licence has been granted and remains in force. Practically, this means that where a product is licensed, the regulatory framework may already have assessed and permitted certain substance quantities. However, the expiry and harmful/unsafe/out-of-specification prohibitions remain relevant. A licensed product can still be prohibited if it is expired or otherwise harmful/unsafe or not in conformity with registered specifications.
3) Restrictions for Chinese proprietary medicines—microbiological limits (Section 4)
Sections 4(1) and 4(2) impose microbiological thresholds on CPMs depending on whether they are for oral consumption or external application. The legal structure is “no person shall import, or sell or supply” CPMs that contain organisms above specified limits.
Oral CPMs (Section 4(1)) are prohibited if they contain, for example:
- total aerobic microbial count of more than 10 per gram or millilitre;
- total yeast and mould count of more than 5 × 10 per gram or millilitre;
- any Escherichia coli in 1 gram or 1 millilitre;
- any Salmonella in 1 gram or 1 millilitre;
- any Staphylococcus aureus in 1 gram or 1 millilitre.
External CPMs (Section 4(2)) are prohibited if they contain, for example:
- total aerobic microbial count of more than 10 per gram or millilitre;
- total yeast and mould count of more than 5 × 10 per gram or millilitre;
- any Pseudomonas aeruginosa in 1 gram or 1 millilitre;
- any Staphylococcus aureus in 1 gram or 1 millilitre.
Fermentation-derived active substance exception (Section 4(3))
Section 4(3) provides a narrow carve-out: the microbiological limits in Section 4(1)(a) and (b) and Section 4(2)(a) and (b) do not apply to CPMs that contain an active substance derived from plants, animals, or a combination thereof, and produced by fermentation processes. This exception is limited: it only addresses the aerobic microbial count and yeast/mould count thresholds, not the “any organism present” prohibitions (such as E. coli, Salmonella, Pseudomonas aeruginosa, or Staphylococcus aureus) as drafted.
4) Prohibition for CPMs containing poisons—conditional allowance (Section 5)
Section 5 is a “poisons control” provision. It states that no person shall import, or sell or supply any CPM that contains any item specified in the Poisons List in the Schedule to the Poisons Act (Cap. 234), unless both conditions are satisfied:
- Condition (a): the item is a substance specified in the first column of the Second Schedule and satisfies the limit or condition in the second column of that Schedule.
- Condition (b): the item is present naturally in the ingredients of the CPM.
This is significant because it does not merely prohibit “poison substances” categorically; it allows certain poisons only where (i) the substance and its quantitative/qualitative limits are expressly permitted in the Second Schedule, and (ii) the poison is naturally present in the ingredients (not added intentionally to achieve an effect, at least on the face of the provision). For compliance, this requires careful ingredient provenance and formulation documentation.
How Is This Legislation Structured?
The Order is structured as follows:
- Section 1 (Citation): provides the short title.
- Section 2 (Definitions): defines “Chinese proprietary medicine” by reference to another Order and defines “expiry date”.
- Section 3 (Restriction on sale, supply and importation of medicinal products): sets general prohibitions based on expiry, safety/specification, and substance quantity limits, plus a specific mercury prohibition for topical antiseptics and a licence-related carve-out.
- Section 4 (Restriction on importation, sale and supply of Chinese proprietary medicine): imposes microbiological limits for oral and external CPMs, with a fermentation-derived active substance exception for certain count limits.
- Section 5 (Prohibition on CPMs containing poisons): prohibits CPMs containing items in the Poisons List unless the Second Schedule permits the substance within specified limits and the poison is naturally present.
- First and Second Schedules: provide the substance quantity framework for Section 3(1)(c) (First Schedule) and the poison-specific limits/conditions for Section 5 (Second Schedule). The extract also indicates a “Poisons allowed in Chinese proprietary medicines” schedule concept.
Who Does This Legislation Apply To?
The Order applies to “a person” and uses verbs that capture the main points of the supply chain: selling,, and. In practice, this includes manufacturers, wholesalers, retailers, importers, distributors, and potentially any intermediary who engages in these activities in Singapore.
For CPMs, the restrictions apply regardless of whether the product is sold directly to consumers or supplied to other businesses, and regardless of whether the product is imported for onward distribution. The legal focus is on the prohibited act (sell/supply/import) in relation to a product that meets the statutory risk criteria (expired, unsafe/out of specification, microbiologically non-compliant, or containing prohibited poisons without meeting the conditions).
Why Is This Legislation Important?
This Order is important because it creates clear, enforceable compliance thresholds that are independent of marketing claims. A practitioner advising a pharmaceutical or traditional medicine business should treat the Order as a “hard stop” document: if a product falls within the prohibited categories, the act of selling, supplying, or importing can be unlawful even if the business believes it is otherwise regulated.
From an enforcement and risk perspective, the Order’s provisions map to common failure points in practice:
- Expiry and stock rotation: Section 3(1)(a) makes expiry-date compliance a direct legal requirement.
- Quality assurance and specification control: Section 3(1)(b) links legality to registered specifications or manufacturer specifications, and to safety.
- Ingredient and formulation limits: Section 3(1)(c) and the First Schedule require substance-level compliance.
- Microbiological testing and batch release: Section 4 requires microbiological limits to be met for oral and external CPMs, with a fermentation-derived exception that must be carefully interpreted and evidenced.
- Poison classification and natural presence: Section 5 requires both schedule-based permission and natural occurrence in ingredients for CPMs containing Poisons List items.
For legal practitioners, the most practical value lies in how the Order interacts with licensing and documentation. The licence carve-out in Section 3(2) is limited to the “excess substances” limb, meaning businesses must still ensure expiry, safety, and specification conformity. For CPMs, compliance is not only about testing results but also about the legal status of the product category and the provenance of ingredients (especially for poison-related provisions).
Related Legislation
- Medicines Act (Cap. 176), in particular Section 30 (authorising provision)
- Poison Act (Cap. 234), including the Poisons List in the Schedule
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (definition of “Chinese proprietary medicine”)
Source Documents
This article provides an overview of the Medicines (Prohibition of Sale, Supply and Importation) Order for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.